Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Nervous System Diseases: full-pipeline trial registry
8 of 24 indexed Nervous System Diseases trials are currently recruiting.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 8 currently recruiting · #686 of 28,707 conditions by registered trial count
Nervous System Diseases: 24 US clinical trials tracked, 8 recruiting.
Nervous System Diseases is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Otsuka Pharmaceutical Development & Commercialization, running 3 of these trials.
Enrollment posture brief
Registry condition nervous-system-diseases
OPEN 8 | RECR 33% | LATE 4 | EARLY 3 | RANK #686 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Nervous System Diseases lists 8 open slots (33% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Nervous System Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Nervous System Diseases is recruiting below its size-band peers.
8 of 24 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Nervous System Diseases trials is spread across many organizations.
Otsuka Pharmaceutical Development & Commercialization accounts for 3 of 24 trials (12.5%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Nervous System Diseases enrolment sits around 90 participants.
Median target enrolment is 90 among the 24 trials that report a genuine target (sentinel values excluded). 14 of those (58.3%) plan for fewer than 100 participants.
-
Nervous System Diseases splits between interventional and observational designs.
16 interventional and 8 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Rett Syndrome Registry
International Rett Syndrome Foundation
NCT05432349
Neurologic Stem Cell Treatment Study
MD Stem Cells
NCT02795052
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
University of Virginia
NCT05565833
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
American Federation of Medical Synergetics
NCT03222375
Brain Connections for Arm Movement After Stroke
VA Office of Research and Development
NCT04286516
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
Kessler Foundation
NCT05731986
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
Jorge Gonzalez-Martinez
NCT06303869
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
Kessler Foundation
NCT05725499
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company
NCT05738486
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Capricor
NCT05126758
Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms
Jonsson Comprehensive Cancer Center
NCT00690196
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
Otsuka Pharmaceutical Development & Commercialization
NCT02192554
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Otsuka Pharmaceutical Development & Commercialization
NCT01862640
pRESET for Occlusive Stroke Treatment
phenox
NCT03994822
Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001667
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization
NCT01922258
Dietary Supplements for the Treatment of Angelman Syndrome
University of California, San Diego
NCT00348933
Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
Elizabeth K Rhodus
NCT05202223
StimRouter Registry Clinical Protocol
Bioness
NCT03913689
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Vanderbilt University Medical Center
NCT03209960
Using Telemedicine to Improve Spasticity Diagnosis Rates
Vanderbilt University Medical Center
NCT03211390
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Dragonfly Research
NCT04837651
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Avidity Biosciences
NCT05479981
Study of Pioglitazone in Sporadic Inclusion Body Myositis
Johns Hopkins University
NCT03440034
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Nervous System Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Nervous System Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Nervous System Diseases page
24 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Nervous System Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Otsuka Pharmaceutical Development & Commercialization sponsors the most Nervous System Diseases trials on record, review their full trial history before evaluating a specific study. See Otsuka Pharmaceutical Development & Commercialization's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nervous System Diseases condition card totals 24 registered trials; most-linked intervention Brexpiprazole, OPC-34712; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.